Amneal Pharmaceuticals has resubmitted its application for IPX203, an investigational extended-release oral formulation of carbidopa and levodopa for treating Parkinson’s disease. The move follows a request by the U.S. Food and Drug Administration (FDA) in July 2023 for more information on the safety of IPX203’s carbidopa component…
Vyalev, a brand name for AbbVie’s ABBV-951 (foslevodopa/foscarbidopa), is now available in Canada as a continuous, subcutaneous (under-the-skin) infusion treatment for people with advanced Parkinson’s disease and motor symptoms that cannot be well controlled with oral medications. “AbbVie is proud to deliver the first new treatment…
Long-term practice of the Chinese martial art tai chi for Parkinson’s disease was shown to ease nonmotor symptoms among patients in a yearlong trial in China. Specifically, improved cognition was seen among people with the neurodegenerative disease after one year of the exercise program, according to study data. Conversely, at…
A Phase 2b trial testing the ability of IRLAB Therapeutics’ investigational oral therapy pirepemat to reduce falls in people with Parkinson’s disease is now expected to complete enrollment by September. Recruitment began last May and was initially expected to finish by the end of 2023, but the…
A once-daily treatment with GT-02287, an oral medication being developed by Gain Therapeutics, protected nerve cells from damage and rescued motor symptoms in a mouse model of Parkinson’s disease associated with mutations in the GBA gene. “We believe the data showing complete…
The department of neurology at Vanderbilt University Medical Center (VUMC) is now part of the CurePSP Center of Care network, which works to enhance public awareness and advance research to better understand atypical parkinsonism. The network focuses on three neurodegenerative diseases: progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and…
People with Parkinson’s disease who are given deep brain stimulation (DBS) tend to have more stable long-term life quality and motor function than do patients treated with medications only, according to a new study. Deep brain stimulation, called DBS for short, is a surgical treatment for Parkinson’s disease…
The first patient has been dosed, and the observation period completed, in a clinical trial in China that’s testing iRegene Therapeutics’ NouvNeu001 cell therapy for moderate to advanced Parkinson’s disease. The Phase 1/2 clinical trial (NCT06167681) started in early January at Beijing Hospital, following a green light from the…
People with epilepsy are at more than double the risk of developing Parkinson’s disease than people without epilepsy, but a cause-and-effect relationship has yet to be established, according to a large study by researchers in South Korea. “To the best of our knowledge, there are three case-control studies ……
The virus that causes COVID-19 is able to infect dopamine-producing brain cells and trigger a specific pattern of dysfunction that has been linked with the development of Parkinson’s disease, a study reports. “Given our findings, we posit that over the coming years, there is a need to closely monitor…
Get regular updates to your inbox.